p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer [version 2; peer review: 2 approved]
Endocrine therapy resistance in Luminal Breast Cancer is a significant issue to be tackled, but currently, no specific biomarker could be used to anticipate this event. p53 mutation is widely known as one of Breast Cancer’s most prominent genetic alterations. Its mutation could generate various effe...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2022-11-01
|
| Series: | F1000Research |
| Subjects: | |
| Online Access: | https://f1000research.com/articles/11-330/v2 |
| _version_ | 1811207016864022528 |
|---|---|
| author | Yohana Azhar Freda Halim Bethy Hernowo Suwarman Suwarman |
| author_facet | Yohana Azhar Freda Halim Bethy Hernowo Suwarman Suwarman |
| author_sort | Yohana Azhar |
| collection | DOAJ |
| description | Endocrine therapy resistance in Luminal Breast Cancer is a significant issue to be tackled, but currently, no specific biomarker could be used to anticipate this event. p53 mutation is widely known as one of Breast Cancer’s most prominent genetic alterations. Its mutation could generate various effects in Estrogen Receptor and Progesterone Receptor molecular works, tangled in events leading to the aggravation of endocrine therapy resistance. Hence the possibility of p53 mutation utilization as an endocrine therapy resistance predictive biomarker is plausible. The purpose of this review is to explore the latest knowledge of p53 role in Estrogen Receptor and Progesterone Receptor molecular actions, thus aggravating the Endocrine Therapy resistance in Luminal Breast Cancer, from which we could define possibilities and limitations to utilize p53 as the predictive biomarker of endocrine therapy resistance in Luminal Breast Cancer. |
| first_indexed | 2024-04-12T03:57:51Z |
| format | Article |
| id | doaj.art-0228e34bb68a4afba0b7d86e7fadd3fd |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-04-12T03:57:51Z |
| publishDate | 2022-11-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-0228e34bb68a4afba0b7d86e7fadd3fd2022-12-22T03:48:47ZengF1000 Research LtdF1000Research2046-14022022-11-0111140986p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer [version 2; peer review: 2 approved]Yohana Azhar0https://orcid.org/0000-0003-2148-0202Freda Halim1https://orcid.org/0000-0002-6982-7669Bethy Hernowo2Suwarman Suwarman3Department of Surgery - Oncology, Head and Neck Division, Hasan Sadikin General Hospital, Universitas Padjajaran, Bandung, IndonesiaDepartment of Surgery, Pelita Harapan University, Tangerang, IndonesiaDepartment of Anatomical Pathology, Universitas Padjajaran, Bandung, West Java, IndonesiaDepartment of Anesthesiology and Intensive Care, Hasan Sadikin General Hospital, Universitas Padjajaran, Bandung, IndonesiaEndocrine therapy resistance in Luminal Breast Cancer is a significant issue to be tackled, but currently, no specific biomarker could be used to anticipate this event. p53 mutation is widely known as one of Breast Cancer’s most prominent genetic alterations. Its mutation could generate various effects in Estrogen Receptor and Progesterone Receptor molecular works, tangled in events leading to the aggravation of endocrine therapy resistance. Hence the possibility of p53 mutation utilization as an endocrine therapy resistance predictive biomarker is plausible. The purpose of this review is to explore the latest knowledge of p53 role in Estrogen Receptor and Progesterone Receptor molecular actions, thus aggravating the Endocrine Therapy resistance in Luminal Breast Cancer, from which we could define possibilities and limitations to utilize p53 as the predictive biomarker of endocrine therapy resistance in Luminal Breast Cancer.https://f1000research.com/articles/11-330/v2p53 predictor endocrine therapy resistance luminal breast cancereng |
| spellingShingle | Yohana Azhar Freda Halim Bethy Hernowo Suwarman Suwarman p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer [version 2; peer review: 2 approved] F1000Research p53 predictor endocrine therapy resistance luminal breast cancer eng |
| title | p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer [version 2; peer review: 2 approved] |
| title_full | p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer [version 2; peer review: 2 approved] |
| title_fullStr | p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer [version 2; peer review: 2 approved] |
| title_full_unstemmed | p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer [version 2; peer review: 2 approved] |
| title_short | p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer [version 2; peer review: 2 approved] |
| title_sort | p53 mutation as plausible predictor for endocrine resistance therapy in luminal breast cancer version 2 peer review 2 approved |
| topic | p53 predictor endocrine therapy resistance luminal breast cancer eng |
| url | https://f1000research.com/articles/11-330/v2 |
| work_keys_str_mv | AT yohanaazhar p53mutationasplausiblepredictorforendocrineresistancetherapyinluminalbreastcancerversion2peerreview2approved AT fredahalim p53mutationasplausiblepredictorforendocrineresistancetherapyinluminalbreastcancerversion2peerreview2approved AT bethyhernowo p53mutationasplausiblepredictorforendocrineresistancetherapyinluminalbreastcancerversion2peerreview2approved AT suwarmansuwarman p53mutationasplausiblepredictorforendocrineresistancetherapyinluminalbreastcancerversion2peerreview2approved |